Avalyn Pharma
Company Snapshot
Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious, rare respiratory diseases. The company's innovative approach aims to enhance the efficacy of existing oral medications by delivering them directly to the lungs, thereby reducing systemic exposure and associated side effects. Avalyn's current pipeline targets pulmonary fibrosis, a life-threatening condition with significant unmet medical needs.
Key Financials
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | Not provided | Not provided |
| Adjusted Net Loss | -$85.2M | -$49.7M |
Balance Sheet
Implied Valuation at Midpoint
Based on price range midpoint and most recent fiscal year data.
S-1 Highlights
Market & Competition
The market for pulmonary fibrosis treatments includes three approved oral antifibrotic therapies: pirfenidone (ESBRIET), nintedanib (OFEV), and nerandomilast (JASCAYD). The company competes with these established therapies, which generated over $4.0 billion in global sales in 2024.
Use of Proceeds
The proceeds from the IPO are expected to be used to advance the clinical development of Avalyn Pharma's product candidates and for general corporate purposes.
Key Risk Factors
- ●The company may face challenges in achieving market acceptance for its product candidates, even if they receive marketing approval.
- ●Avalyn Pharma may encounter difficulties in managing its growth, which could disrupt operations.
Deal Structure
Reported Broker Availability
Reported by users or publicly disclosed. Information is for reference only.